# BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Source: https://onco.cc/trials/nct05555251/  
OnCo record `nct05555251` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BI-1607 run by BioInvent International AB, terminated.

## Summary

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05555251 by BioInvent International AB, with 18 participants enrolled, started 2022-07-28. Conditions recorded: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma and Metastatic Gastric Adenocarcinoma. Interventions recorded: BI-1607, BI-1607 and Trastuzumab.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05555251
- Phase: 1/2
- Setting: Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
- Sponsor: BioInvent International AB
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT05555251: https://clinicaltrials.gov/study/NCT05555251

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/)
- drugs: [BI-1607](https://onco.cc/drugs/bi-1607/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/)

---
JSON: https://onco.cc/api/v1/entities/nct05555251.json